TCI Wealth Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

TCI Wealth Advisors’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10	Closed	–	–	2667
2022 Q2	$0	Hold	10	–	–	﹤0.01%	2587
2022 Q1	$0	Sell	10 -10	-50%	-$282	﹤0.01%	2529
2021 Q4	$1K	Sell	20 -10	-33%	-$375	﹤0.01%	2267
2021 Q3	$1K	Hold	30	–	–	﹤0.01%	2336
2021 Q2	$1K	Hold	30	–	–	﹤0.01%	2275
2021 Q1	$1K	Sell	30 -10	-25%	-$375	﹤0.01%	2130
2020 Q4	$1K	Sell	40 -10	-20%	-$304	﹤0.01%	1492
2020 Q3	$1K	Sell	50 -90	-64%	-$2.65K	﹤0.01%	1478
2020 Q2	$4K	Buy	+140	New	+$3.78K	﹤0.01%	850

Other funds holding GERM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TCI Wealth Advisors's GERM Position: Q3 2022 in Review

TCI Wealth Advisors sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2022, closing a stake of 10 shares.

TCI Wealth Advisors first reported a position in GERM in Q2 2020 and held it in 9 quarters. The position peaked at $4K in Q2 2020. 22 funds tracked by Wall St. Rank hold GERM as of Q3 2022.

TCI Wealth Advisors reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2022 after selling out during the quarter.
TCI Wealth Advisors sold 10 Amplify Treatments, Testing and Advancements ETF shares in Q3 2022.
TCI Wealth Advisors first reported a position in Amplify Treatments, Testing and Advancements ETF in Q2 2020 and held it in 9 quarters.
TCI Wealth Advisors's Amplify Treatments, Testing and Advancements ETF position peaked at $4K in Q2 2020.
22 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2022.

Based on TCI Wealth Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.